Treatment with high-dose rifamycin (HDR)-based regimens was not associated with an increased risk for severe adverse events (SAE) compared with standard-dose rifamycin (SDR)-based regimens among patients with tuberculosis (TB) infection, according to results of a study published in Thorax.